Navigation Links
Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Date:4/26/2012

reated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment.  The use of Vimpat® in patients with severe hepatic impairment is not recommended. 

For full prescribing information on Vimpat®, visit http://www.vimpat.com/prescribing-information.aspx. (Accessed 18th October, 2011)

For more information on Vimpat®, visit www.Vimpat.com or contact UCB at (800) 477-7877.

Vimpat® (C-V) is a Schedule V controlled substance. 
Vimpat® is a registered trademark under license from Harris FRC Corporation.

Important safety information about Vimpat® in the EU and EEA

Vimpat® (lacosamide) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older. Vimpat® solution for infusion is an alternative for patients when oral administration is temporarily not feasible. Contraindications: Hypersensitivity to the active substance or any of the excipients; known second- or third-degree atrioventricular (AV) block. Special warnings and precautions for use: Treatment with Vimpat® has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. Prolongations in PR interval with Vimpat®  have been observed in clinical studies. Cases with second- and third-degree AV block associated with Vimpat® treatment have been reported in post-marketing experience. Vimpat® should be used with caution in patients with known cond
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Medical Equipment Solutions, ... been awarded a Department of Defense (US Army) contract ... supply a mobile MRI diagnostic machine and technical support ... (WOSB) through the Small Business Administration (SBA), Medical Equipment ... field with the latest medical diagnostic equipment. The SBA ...
(Date:7/30/2014)... SUNNYVALE, California , July 30, 2014 /PRNewswire/ ... GPU technology and CUDA programming expertise to big ... other markets  eInfochips, a leading engineering ... to clients to develop NVIDIA GPU-powered solutions for ... , high-performance computing (HPC), industrial ...
(Date:7/29/2014)... 29, 2014 Amgen (NASDAQ: AMGN ... of 2014. Key results include: , Total revenues ... product sales growth driven by strong performance across the ... (carfilzomib), Prolia ® (denosumab) and XGEVA ® ... $2.37, driven by higher revenues and a significant increase ...
Breaking Medicine Technology:Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... , , FREMONT, Calif., Nov. 24 ... its Plan of Reorganization and Disclosure Statement today, November 24, ... of Delaware. A hearing to consider approval of the Disclosure ... hearing on the confirmation of the Plan scheduled for January ...
... , ... developer and marketer of the VerifyNow® System, the first rapid ... multiple antiplatelet agents (e.g. Plavix® and aspirin), announced today that ... J. Tibbitts, Chief Financial Officer of Accumetrics, will be presenting ...
Cached Medicine Technology:Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2
(Date:7/30/2014)... SF Cable, distributor of the highest ... on the internet with guaranteed customer satisfaction announces the ... two colors. These lightning cords are MFI certified to ... quality SF Cable Lightning to USB Cables ... faster charging and syncing. Compatible with the iPhone 5S/5C/5 ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... Louisville, KY (PRWEB) July 30, 2014 ... is pleased to announce the launch of its ... free, online resource for medical professionals and equipment vendors. ... trade shows and conventions in the United States and ... on the calendar, and that number is always growing. ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The Ehlers-Danlos ... Board of Directors. Sandra Aiken Chack will serve as ... at the EDNF 2014 Annual Learning Conference in Houston, ... has an ambitious agenda ahead of us. From the ... & Research at the Greater Baltimore Medical Center to ...
(Date:7/30/2014)... 30, 2014 The American Telemedicine ... Sens. Thad Cochran (R-MS) and Roger Wicker (R-MS) ... telemedicine coverage under Medicare, Medicaid and Federal Communications ... Mississippi Republicans, introduced the Telehealth Enhancement Act as ... version, H.R. 3306, introduced by Rep. Gregg Harper ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2
... Rebuild Schools and Clinics, LOS ANGELES, May 14 ... relief agency,today announced that it is responding with aid ... earthquake has mobilized relief agencies from,around the world and ... the call., The Chinese Army is taking the ...
... Offers Tips to Help Make Healthy Choices on the ... Swimsuit season is right around the,corner and for many ... though, cutting back on calories and finding time to ... CareerBuilder.com survey reports,that 45 percent of workers have gained ...
... by Johns Hopkins doctors has fine-tuned the dosage and ... patients with strokes caused by bleeding within the brain. ... Stroke Conference in Nice, France, has been shown to ... typically lethal subset of stroke. , "We,ve gone from ...
... children can be picky eaters,spooked by strong flavors or ... the taste of the pickiest eaters. But just because ... family can,t,enjoy something with more zip. To help parents ... without spending all night in the kitchen,Mealtime.org has devised ...
... Stable Treatment for Hemophilia With ... Patients, PRINCETON, N.J., May 13 Novo ... Administration (FDA) has approved,NovoSeven(R) RT (Coagulation Factor VIIa ... recombinant product available,for the treatment of bleeding episodes ...
... Ill., May 13 Z Trim Holdings, Inc.,(Amex: ... statements,for the fiscal year ended December 31, 2007 contained ... accounting,firm, Blackman Kallick LLP. This announcement is being made ... which requires separate disclosure,of receipt of an audit opinion ...
Cached Medicine News:Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 2Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 3Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 4Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Personalized Plates for Picky Palates: Moms can Satisfy all With One Recipe, Four Ways 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 3Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 4Health News:Z Trim Holdings, Inc. Audit Report Contains 'Going Concern' Qualification 2
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
Intended for the quantitative determination of creatinine in serum, plasma, or urine. Reaction: Endpoint. Wavelength: 340 nm. Linearity: 10 mg/dL (880 mol/L). Two vials, dry powder reagents....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
Medicine Products: